查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1933317

全球重组疫苗市场：市场规模、占有率、成长率、产业分析、依类型、应用和地区划分的考量、未来预测（2026-2034）

Recombinant Vaccines Market Size, Share, Growth and Global Industry Analysis By Type & Application, Regional Insights and Forecast to 2026-2034
出版日期: | 出版商: Fortune Business Insights Pvt. Ltd. | 英文 167 Pages | 商品交期: 请询问到货日

价格

重组疫苗市场成长因素

由于传染病日益流行、对安全有效疫苗的需求不断成长以及主要製药公司的策略投资，全球重组疫苗市场预计将稳步成长。该市场在2025年的价值为415.9亿美元，预计2026年达到448.6亿美元，到2034年成长至1090.6亿美元，预测期内年复合成长率为10.62%。

重组疫苗利用基因工程技术标靶特定基因或蛋白质，诱发有针对性的免疫反应。与传统疫苗相比，它们具有高特异性、可扩展性和安全性等优势。例如，2023年5月，GSK的重组疫苗Aleksvy获得美国FDA批准，用于预防60岁及以上成年人由呼吸道合胞病毒（RSV）引起的下呼吸道疾病。

市场由Bavarian Nordic、GSK plc、Pfizer Inc.、Merck & Co., Inc.等大型公司主导，它们强大的产品组合和全球分销网路巩固了其领先地位。

市场动态

市场驱动因素

关键成长因素之一是研发投入的增加。重组疫苗无需使用完整的病原体即可开发，降低感染风险和不良反应。各公司正大力投资研发此类疫苗，以满足不断成长的需求。例如，2024年9月，美国国际发展金融公司（DFC）向Panacea Biotech公司提供了一笔高达2000万美元的贷款，用于资助其基于IPV的重组脊髓灰质炎疫苗EasySix的研发。

市场限制因子

疫苗研发的高昂成本和临床试验失败的风险限制市场成长。疫苗生产需要复杂的细胞培养系统、纯化过程和昂贵的生物反应器，增加了资本支出。例如，2023年8月，GSK plc投资2.706亿美元，用于扩大其在比利时的重组疫苗产能。同样，2025年8月，美国卫生与公共服务部（HHS）终止了生物医学高级研究与发展局（BARDA）的mRNA疫苗研发活动，理由是该疫苗对某些传染病的保护作用不足。

市场机会

治疗性疫苗的研发为市场扩张提供了巨大的机会。针对癌症和病毒感染的重组疫苗具有标靶治疗优势。2025年3月，ImmunityBio与Urology Partners合作，扩大膀胱癌患者使用重组卡介苗（rBCG）免疫疗法的途径。同样，2024年6月，Moderna和Merck & Co., Inc.公布了针对黑色素瘤患者的个人化重组mRNA癌症疫苗II期临床试验的积极资料。

市场挑战

冷链物流和供应方面的挑战仍然是重大障碍。重组疫苗对温度敏感，需要严格冷藏才能维持效力。中低收入国家往往面临基础建设的挑战，限制了疫苗的供应。例如，2021年9月，世界卫生组织向45个国家提供了350台超低温冰箱，以应对这些限制。

市场趋势

一个值得关注的趋势是联合疫苗的研发，这种疫苗只需一剂即可预防多种疾病。这提高了接种依从性，并减少了储存方面的挑战。2024年12月，Sanofi公司针对50岁及以上成年人研发的流感和新冠肺炎联合疫苗获得了快速通道资格认定。

市场区隔分析

依类型划分：

  • 由于次单位疫苗具有高稳定性、安全性和靶向免疫反应等优点，预计到2026年，亚单位疫苗将占据市场主导地位，市场占有率高达77.11%。例如，印度在其 "新冠安全使命" （Mission COVID Suraksha）计划下研发了蛋白质亚单位新冠疫苗 "ORBEVAX™" 。
  • 载体疫苗也越来越受欢迎，但其市场占有率仍然相对较小。

依疾病分类：

  • 受疾病盛行率上升和产能扩张的推动，HPV疫苗将在2026年占据市场主导地位，市场占有率达38.29%。Merck & Co., Inc.于2022年4月扩建了位于维吉尼亚州埃尔克顿的工厂，以供应HPV疫苗。
  • 预计B肝疫苗在预测期内将以15.1%的年复合成长率成长。

依给药途径分类：

  • 由于注射疫苗具有高生物利用度和标靶作用，到2026年，注射疫苗将占据主导地位，市场占有率达78.38%。例如，Valneva公司于2023年11月获得了FDA批准的首个注射型屈公病疫苗Ixchiq。
  • 预计口服疫苗将显着成长。

依通路划分：

  • 2024年，政府供应商占据主导地位，他们积极推广常规免疫接种计划，尤其是在中低收入地区。
  • 2026年，医院和零售药局的市场占有率达到60.89%。策略伙伴关係进一步巩固了这个通路，例如Merck与全球疫苗免疫联盟（Gavi）和联合国儿童基金会（UNICEF）合作，计划到2025年供应1.15亿剂HPV疫苗。

区域展望

  • 北美成为最大的市场，2025年市场规模达到177.5亿美元，预计到2026年将成长至192.2亿美元，这主要得益于其先进的医疗保健基础设施和较高的疫苗接种率。
  • 2025年，欧洲市场规模达到81.1亿美元，实现强劲成长（年复合成长率8.68%）。英国和德国市场预计到2026年将分别达到17.3亿美元和21.1亿美元。
  • 到2025年，亚太地区市场规模达到97.4亿美元；到2026年，日本、中国和印度市场规模分别达到16.1亿美元、25.3亿美元和22.3亿美元。
  • 到2025年，拉丁美洲市场规模达到20.9亿美元；中东和非洲（GCC）地区市场规模达到1.8亿美元，这两个地区都温和成长。

目录

第1章 引言

第2章 执行摘要

第3章 市场动态

  • 市场驱动因素
  • 市场限制因素
  • 市场机会
  • 市场趋势

第4章 主要考察

  • 各国及地区主要疾病概览（2025年）
  • 各国及地区监理状况（2025年）
  • 主要公司研发管线分析
  • 疫苗市场技术进步
  • 主要公司新产品发布
  • 关键产业趋势：併购、业务合作等等。

第5章 全球重组疫苗市场分析：洞察与预测（2021-2034）

  • 市场分析、洞察与预测：依类型划分
    • 次单位疫苗
    • 载体疫苗
  • 市场分析、洞察与预测：依疾病划分
    • 人类乳突病毒（HPV）
    • 带状疱疹
    • B型肝炎
    • 其他
  • 市场分析、洞察与预测：依给药途径划分
    • 口服
    • 注射
  • 市场分析、洞察与预测：依通路划分
    • 医院和零售药局
    • 政府供应商
    • 其他
  • 市场分析、洞察与预测：依地区划分
    • 北美
    • 欧洲
    • 亚太地区
    • 拉丁美洲
    • 中东和非洲

第6章 北美重组疫苗市场分析：洞察与预测（2021-2034）

  • 依国家划分
    • 美国
    • 加拿大

第7章 欧洲重组疫苗市场分析：洞察与预测（2021-2034）

  • 依国家划分
    • 德国
    • 英国
    • 法国
    • 义大利
    • 西班牙
    • 斯堪的纳维亚
    • 其他欧洲国家

第8章 亚太地区重组疫苗市场分析：洞察与预测（2021-2034）

  • 依国家划分
    • 中国
    • 日本
    • 印度
    • 澳洲
    • 东南亚
    • 亚太其他地区

第9章 拉丁美洲重组疫苗市场分析：洞察与预测（2021-2034）

  • 依国家划分
    • 巴西
    • 墨西哥
    • 拉丁美洲其他地区美国

第10章 中东与非洲重组疫苗市场分析：洞察与预测（2021-2034）

  • 依国家划分
    • GCC国家
    • 南非
    • 中东和非洲其他地区

第11章 竞争分析

  • 全球市场占有率分析（2025）
  • 公司简介
  • Bavarian Nordic
  • GSK plc
  • Pfizer Inc.
  • Merck &Co., Inc.
  • CSL
  • Mitsubishi Chemical Group Corporation
  • AstraZeneca
  • Sanofi
  • EMERGENT
  • BIKEN.
Product Code: FBI101935

Growth Factors of recombinant vaccines Market

The global recombinant vaccines market is poised for robust growth owing to increasing prevalence of infectious diseases, rising demand for safe and effective vaccines, and strategic investments by leading pharmaceutical companies. The market was valued at USD 41.59 billion in 2025, expected to reach USD 44.86 billion in 2026, and projected to grow to USD 109.06 billion by 2034, reflecting a CAGR of 10.62% during the forecast period.

Recombinant vaccines are genetically engineered vaccines that target specific genes or proteins to elicit a focused immune response. These vaccines offer high specificity, scalability, and safety advantages compared to traditional vaccines. For example, in May 2023, GSK received U.S. FDA approval for Arexvy, a recombinant vaccine for preventing lower respiratory tract disease caused by RSV in adults aged 60 years and older.

The market is dominated by key players such as Bavarian Nordic, GSK plc, Pfizer Inc., and Merck & Co., Inc., whose strong product portfolios and global distribution networks contribute to their leading positions.

Market Dynamics

Market Drivers

One of the major growth drivers is the rising investment in research and development. Recombinant vaccines can be developed without using the entire pathogen, reducing the risk of infection and adverse events. Companies are heavily investing in developing these vaccines to meet growing demand. For instance, in September 2024, the U.S. International Development Finance Corporation (DFC) provided a loan of up to USD 20 million to Panacea Biotec Limited for developing an IPV-based recombinant polio vaccine, EasySix.

Market Restraints

The high cost of vaccine development and risk of clinical trial failures restrict market growth. Production involves advanced cell culture systems, purification processes, and expensive bioreactors, increasing capital expenditure. For example, in August 2023, GSK plc invested USD 270.6 million to expand recombinant vaccine capacity in Belgium. Similarly, in August 2025, the U.S. HHS terminated mRNA vaccine development activities under BARDA due to ineffective protection against certain infections.

Market Opportunities

The development of therapeutic vaccines offers significant opportunities for market expansion. Recombinant vaccines for cancer or viral infections provide targeted therapeutic benefits. In March 2025, ImmunityBio, Inc. partnered with U.S. Urology Partners to expand access for recombinant BCG (rBCG) immunotherapy for bladder cancer. Likewise, in June 2024, Moderna and Merck reported positive Phase 2 data for a personalized recombinant mRNA cancer vaccine in melanoma patients.

Market Challenges

Cold chain logistics and supply challenges remain critical barriers. Recombinant vaccines are temperature-sensitive, requiring strict cold storage to maintain efficacy. Low- and middle-income countries often face infrastructure challenges, restricting vaccine accessibility. For example, in September 2021, the WHO delivered 350 ultra-cold chain freezers to over 45 countries to address these limitations.

Market Trends

A prominent trend is the development of combination vaccines that provide protection against multiple diseases in a single shot, improving compliance and reducing storage challenges. In December 2024, Sanofi received Fast Track designation for combination vaccines targeting influenza and COVID-19 in adults above 50 years.

Segmentation Analysis

By Type:

  • Subunit vaccines dominated in 2026 with 77.11% share, driven by high stability, safety, and targeted immune response. For example, India developed ORBEVAXTM, a protein subunit COVID-19 vaccine, under the Mission COVID Suraksha initiative.
  • Vector-based vaccines are also gaining traction but represent a smaller share.

By Disease Indication:

  • HPV vaccines led in 2026 with 38.29% share, supported by rising disease prevalence and expanded production capacities. Merck & Co., Inc. expanded its Elkton, Virginia facility in April 2022 for HPV vaccine supply.
  • Hepatitis B vaccines are projected to grow at a 15.1% CAGR during the forecast period.

By Route of Administration:

  • Parenteral vaccines dominated in 2026 with 78.38% share, due to greater bioavailability and site-specific action. For instance, Valneva SE received FDA approval in November 2023 for Ixchiq, the first parenteral chikungunya vaccine.
  • Oral vaccines are expected to grow at a significant rate.

By Distribution Channel:

  • Government suppliers dominated in 2024, facilitating routine vaccination programs, especially in low- and middle-income regions.
  • Hospitals and retail pharmacies held 60.89% share in 2026. Strategic collaborations, such as Merck's partnership with Gavi and UNICEF to supply 115 million HPV vaccine doses by 2025, further strengthened this channel.

Regional Outlook

  • North America dominated with USD 17.75 billion in 2025, growing to USD 19.22 billion in 2026, driven by advanced healthcare infrastructure and high vaccine adoption.
  • Europe was valued at USD 8.11 billion in 2025, with projected strong growth (8.68% CAGR). The UK and Germany markets are expected to reach USD 1.73 billion and USD 2.11 billion by 2026, respectively.
  • Asia Pacific reached USD 9.74 billion in 2025, with Japan, China, and India markets projected at USD 1.61 billion, 2.53 billion, and 2.23 billion by 2026, respectively.
  • Latin America recorded USD 2.09 billion in 2025, while Middle East & Africa (GCC) stood at USD 0.18 billion in 2025, with moderate growth expected.

Competitive Landscape

The market is semi-consolidated, dominated by Bavarian Nordic, GSK plc, Pfizer Inc., and Merck & Co., Inc.. Other players include Mitsubishi Chemical, AstraZeneca, Sanofi, EMERGENT, and BIKEN, focusing on product innovation, strategic partnerships, and geographic expansion.

Key Developments:

  • July 2025: GSK approved prefilled syringe of Shingrix (zoster vaccine).
  • April 2025: GC Biopharma approved for anthrax vaccine BARYTHRAX in South Korea.
  • March 2024: IIT Guwahati launched recombinant vaccine for Swine Fever Virus.
  • May 2023: Pfizer received FDA approval for ABRYSVO (RSV vaccine).

Conclusion

The global recombinant vaccines market is projected to grow from USD 41.59 billion in 2025 to USD 109.06 billion by 2034, at a CAGR of 10.62%. Growth is driven by rising infectious disease prevalence, investments in R&D, development of subunit and combination vaccines, and expansion of therapeutic applications. Despite challenges such as high manufacturing costs and cold chain logistics, opportunities in HPV, hepatitis B, and therapeutic cancer vaccines, along with strategic collaborations, will continue to propel market expansion globally.

Segmentation By Type

  • Subunit Vaccines
  • Vector-Based Vaccines

By Disease Indication

  • HPV
  • Herpes Zoster
  • Hepatitis B
  • Others

By Route of Administration

  • Parenteral
  • Others

By Distribution Channel

  • Hospital & Retail Pharmacies
  • Government Suppliers
  • Others

By Region

  • North America (By Type, Disease Indication, Route of Administration, Distribution Channel, and Country)
    • U.S.
    • Canada
  • Europe (By Type, Disease Indication, Route of Administration, Distribution Channel, and Country/Sub-region)
    • Germany
    • U.K.
    • France
    • Spain
    • Italy
    • Scandinavia
    • Rest of Europe
  • Asia Pacific (By Type, Disease Indication, Route of Administration, Distribution Channel, and Country/Sub-region)
    • China
    • Japan
    • India
    • Australia
    • Southeast Asia
    • Rest of Asia Pacific
  • Latin America (By Type, Disease Indication, Route of Administration, Distribution Channel, and Country/Sub-region)
    • Brazil
    • Mexico
    • Rest of Latin America
  • Middle East & Africa (By Type, Disease Indication, Route of Administration, Distribution Channel, and Country/Sub-region)
    • GCC
    • South Africa
  • Rest of the Middle East & Africa

Table of Content

1. Introduction

  • 1.1. Research Scope
  • 1.2. Market Segmentation
  • 1.3. Research Methodology
  • 1.4. Definitions and Assumptions

2. Executive Summary

3. Market Dynamics

  • 3.1. Market Drivers
  • 3.2. Market Restraints
  • 3.3. Market Opportunities
  • 3.4. Market Trends

4. Key Insights

  • 4.1. Overview of Key Diseases, By Key Countries/ Region, 2025
  • 4.2. Regulatory Scenario by Key Countries/ Region, 2025
  • 4.3. Pipeline Analysis, By Key Players
  • 4.4. Technological Advancements in the Vaccines Market
  • 4.5. New Product Launches, By Key Players
  • 4.6. Key Industry Developments (Mergers, Acquisitions, Partnerships, etc.)

5. Global Recombinant Vaccines Market Analysis, Insights and Forecast, 2021-2034

  • 5.1. Market Analysis, Insights and Forecast - By Type
    • 5.1.1. Subunit Vaccines
    • 5.1.2. Vector-Based Vaccines
  • 5.2. Market Analysis, Insights and Forecast - By Disease Indication
    • 5.2.1. Human Papillomavirus (HPV)
    • 5.2.2. Herpes Zoster
    • 5.2.3. Hepatitis B
    • 5.2.4. Others
  • 5.3. Market Analysis, Insights and Forecast - By Route of Administration
    • 5.3.1. Oral
    • 5.3.2. Parenteral
  • 5.4. Market Analysis, Insights and Forecast - By Distribution Channel
    • 5.4.1. Hospital & Retail Pharmacies
    • 5.4.2. Government Suppliers
    • 5.4.3. Others
  • 5.5. Market Analysis, Insights and Forecast - Region
    • 5.5.1. North America
    • 5.5.2. Europe
    • 5.5.3. Asia Pacific
    • 5.5.4. Latin America
    • 5.5.5. Middle East & Africa

6. North America Recombinant Vaccines Market Analysis, Insights and Forecast, 2021-2034

  • 6.1. Market Analysis, Insights and Forecast - By Type
    • 6.1.1. Subunit Vaccines
    • 6.1.2. Vector-Based Vaccines
  • 6.2. Market Analysis, Insights and Forecast - By Disease Indication
    • 6.2.1. Human Papillomavirus (HPV)
    • 6.2.2. Herpes Zoster
    • 6.2.3. Hepatitis B
    • 6.2.4. Others
  • 6.3. Market Analysis, Insights and Forecast - By Route of Administration
    • 6.3.1. Oral
    • 6.3.2. Parenteral
  • 6.4. Market Analysis, Insights and Forecast - By Distribution Channel
    • 6.4.1. Hospital & Retail Pharmacies
    • 6.4.2. Government Suppliers
    • 6.4.3. Others
  • 6.5. Market Analysis, Insights and Forecast - By Country
    • 6.5.1. U.S.
    • 6.5.2. Canada

7. Europe Recombinant Vaccines Market Analysis, Insights and Forecast, 2021-2034

  • 7.1. Market Analysis, Insights and Forecast - By Type
    • 7.1.1. Subunit Vaccines
    • 7.1.2. Vector-Based Vaccines
  • 7.2. Market Analysis, Insights and Forecast - By Disease Indication
    • 7.2.1. Human Papillomavirus (HPV)
    • 7.2.2. Herpes Zoster
    • 7.2.3. Hepatitis B
    • 7.2.4. Others
  • 7.3. Market Analysis, Insights and Forecast - By Route of Administration
    • 7.3.1. Oral
    • 7.3.2. Parenteral
  • 7.4. Market Analysis, Insights and Forecast - By Distribution Channel
    • 7.4.1. Hospital & Retail Pharmacies
    • 7.4.2. Government Suppliers
    • 7.4.3. Others
  • 7.5. Market Analysis, Insights and Forecast - By Country/ Sub-Region
    • 7.5.1. Germany
    • 7.5.2. U.K.
    • 7.5.3. France
    • 7.5.4. Italy
    • 7.5.5. Spain
    • 7.5.6. Scandinavia
    • 7.5.7. Rest of Europe

8. Asia Pacific Recombinant Vaccines Market Analysis, Insights and Forecast, 2021-2034

  • 8.1. Market Analysis, Insights and Forecast - By Type
    • 8.1.1. Subunit Vaccines
    • 8.1.2. Vector-Based Vaccines
  • 8.2. Market Analysis, Insights and Forecast - By Disease Indication
    • 8.2.1. Human Papillomavirus (HPV)
    • 8.2.2. Herpes Zoster
    • 8.2.3. Hepatitis B
    • 8.2.4. Others
  • 8.3. Market Analysis, Insights and Forecast - By Route of Administration
    • 8.3.1. Oral
    • 8.3.2. Parenteral
  • 8.4. Market Analysis, Insights and Forecast - By Distribution Channel
    • 8.4.1. Hospital & Retail Pharmacies
    • 8.4.2. Government Suppliers
    • 8.4.3. Others
  • 8.5. Market Analysis, Insights and Forecast - By Country/ Sub-Region
    • 8.5.1. China
    • 8.5.2. Japan
    • 8.5.3. India
    • 8.5.4. Australia
    • 8.5.5. Southeast Asia
    • 8.5.6. Rest of Asia Pacific

9. Latin America Recombinant Vaccines Market Analysis, Insights and Forecast, 2021-2034

  • 9.1. Market Analysis, Insights and Forecast - By Type
    • 9.1.1. Subunit Vaccines
    • 9.1.2. Vector-Based Vaccines
  • 9.2. Market Analysis, Insights and Forecast - By Disease Indication
    • 9.2.1. Human Papillomavirus (HPV)
    • 9.2.2. Herpes Zoster
    • 9.2.3. Hepatitis B
    • 9.2.4. Others
  • 9.3. Market Analysis, Insights and Forecast - By Route of Administration
    • 9.3.1. Oral
    • 9.3.2. Parenteral
  • 9.4. Market Analysis, Insights and Forecast - By Distribution Channel
    • 9.4.1. Hospital & Retail Pharmacies
    • 9.4.2. Government Suppliers
    • 9.4.3. Others
  • 9.5. Market Analysis, Insights and Forecast - By Country/ Sub-Region
    • 9.5.1. Brazil
    • 9.5.2. Mexico
    • 9.5.3. Rest of Latin America

10. Middle East & Africa Recombinant Vaccines Market Analysis, Insights and Forecast, 2021-2034

  • 10.1. Market Analysis, Insights and Forecast - By Type
    • 10.1.1. Subunit Vaccines
    • 10.1.2. Vector-Based Vaccines
  • 10.2. Market Analysis, Insights and Forecast - By Disease Indication
    • 10.2.1. Human Papillomavirus (HPV)
    • 10.2.2. Herpes Zoster
    • 10.2.3. Hepatitis B
    • 10.2.4. Others
  • 10.3. Market Analysis, Insights and Forecast - By Route of Administration
    • 10.3.1. Oral
    • 10.3.2. Parenteral
  • 10.4. Market Analysis, Insights and Forecast - By Distribution Channel
    • 10.4.1. Hospital & Retail Pharmacies
    • 10.4.2. Government Suppliers
    • 10.4.3. Others
  • 10.5. Market Analysis, Insights and Forecast - By Country/ Sub-Region
    • 10.5.1. GCC
    • 10.5.2. South Africa
    • 10.5.3. Rest of Middle East & Africa

11. Competitive Analysis

  • 11.1. Global Market Share Analysis (2025)
  • 11.2. Company Profiles (Overview, Products, SWOT Analysis, Recent Developments, Strategies, Financials (Based on Availability))
    • 11.2.1. Bavarian Nordic
    • 11.2.2. GSK plc
    • 11.2.3. Pfizer Inc.
    • 11.2.4. Merck & Co., Inc.
    • 11.2.5. CSL
    • 11.2.6. Mitsubishi Chemical Group Corporation
    • 11.2.7. AstraZeneca
    • 11.2.8. Sanofi
    • 11.2.9. EMERGENT
    • 11.2.10. BIKEN.

List of Tables

  • Table 1: Global Recombinant Vaccines Market Revenue (USD billion) Forecast, by Type, 2021-2034
  • Table 2: Global Recombinant Vaccines Market Revenue (USD billion) Forecast, by Disease Indication, 2021-2034
  • Table 3: Global Recombinant Vaccines Market Revenue (USD billion) Forecast, by Route of Administration, 2021-2034
  • Table 4: Global Recombinant Vaccines Market Revenue (USD billion) Forecast, by Distribution Channel, 2021-2034
  • Table 5: Global Recombinant Vaccines Market Revenue (USD billion) Forecast, by Region, 2021-2034
  • Table 6: North America Recombinant Vaccines Market Revenue (USD billion) Forecast, by Type, 2021-2034
  • Table 7: North America Recombinant Vaccines Market Revenue (USD billion) Forecast, by Disease Indication, 2021-2034
  • Table 8: North America Recombinant Vaccines Market Revenue (USD billion) Forecast, by Route of Administration, 2021-2034
  • Table 9: North America Recombinant Vaccines Market Revenue (USD billion) Forecast, by Distribution Channel, 2021-2034
  • Table 10: North America Recombinant Vaccines Market Revenue (USD billion) Forecast, By Country, 2021-2034
  • Table 11: Europe Recombinant Vaccines Market Revenue (USD billion) Forecast, by Type, 2021-2034
  • Table 12: Europe Recombinant Vaccines Market Revenue (USD billion) Forecast, by Disease Indication, 2021-2034
  • Table 13: Europe Recombinant Vaccines Market Revenue (USD billion) Forecast, by Route of Administration, 2021-2034
  • Table 14: Europe Recombinant Vaccines Market Revenue (USD billion) Forecast, by Distribution Channel, 2021-2034
  • Table 15: Europe Recombinant Vaccines Market Revenue (USD billion) Forecast, By Country/ Sub-region, 2021-2034
  • Table 16: Asia Pacific Recombinant Vaccines Market Revenue (USD billion) Forecast, by Type, 2021-2034
  • Table 17: Asia Pacific Recombinant Vaccines Market Revenue (USD billion) Forecast, by Disease Indication, 2021-2034
  • Table 18: Asia Pacific Recombinant Vaccines Market Revenue (USD billion) Forecast, by Route of Administration, 2021-2034
  • Table 19: Asia Pacific Recombinant Vaccines Market Revenue (USD billion) Forecast, by Distribution Channel, 2021-2034
  • Table 20: Asia Pacific Recombinant Vaccines Market Revenue (USD billion) Forecast, By Country/ Sub-region, 2021-2034
  • Table 21: Latin America Recombinant Vaccines Market Revenue (USD billion) Forecast, by Type, 2021-2034
  • Table 22: Latin America Recombinant Vaccines Market Revenue (USD billion) Forecast, by Disease Indication, 2021-2034
  • Table 23: Latin America Recombinant Vaccines Market Revenue (USD billion) Forecast, by Route of Administration, 2021-2034
  • Table 24: Latin America Recombinant Vaccines Market Revenue (USD billion) Forecast, by Distribution Channel, 2021-2034
  • Table 25: Latin America Recombinant Vaccines Market Revenue (USD billion) Forecast, By Country/ Sub-region, 2021-2034
  • Table 26: Middle East & Africa Recombinant Vaccines Market Revenue (USD billion) Forecast, by Type, 2021-2034
  • Table 27: Middle East & Africa Recombinant Vaccines Market Revenue (USD billion) Forecast, by Disease Indication, 2021-2034
  • Table 28: Middle East & Africa Recombinant Vaccines Market Revenue (USD billion) Forecast, by Route of Administration, 2021-2034
  • Table 29: Middle East & Africa Recombinant Vaccines Market Revenue (USD billion) Forecast, by Distribution Channel, 2021-2034
  • Table 30: Middle East & Africa Recombinant Vaccines Market Revenue (USD billion) Forecast, By Country/ Sub-region, 2021-2034

List of Figures

  • Figure 1: Global Recombinant Vaccines Market Revenue Breakdown (USD billion, %) by Region, 2025 & 2034
  • Figure 2: Global Recombinant Vaccines Market Value Share (%), by Type, 2025 & 2034
  • Figure 3: Global Recombinant Vaccines Market Value Share (%), by Disease Indication, 2025 & 2034
  • Figure 4: Global Recombinant Vaccines Market Value Share (%), by Route of Administration, 2025 & 2034
  • Figure 5: Global Recombinant Vaccines Market Value Share (%), by Distribution Channel, 2025 & 2034
  • Figure 6: Global Recombinant Vaccines Market Value Share (%), by Region, 2025 & 2034
  • Figure 7: North America Recombinant Vaccines Market Value (USD billion), by Type, 2025 & 2034
  • Figure 8: North America Recombinant Vaccines Market Value Share (%), by Type, 2025
  • Figure 9: North America Recombinant Vaccines Market Value (USD billion), by Disease Indication, 2025 & 2034
  • Figure 10: North America Recombinant Vaccines Market Value Share (%), by Disease Indication, 2025
  • Figure 11: North America Recombinant Vaccines Market Value (USD billion), by Route of Administration, 2025 & 2034
  • Figure 12: North America Recombinant Vaccines Market Value Share (%), by Route of Administration, 2025
  • Figure 13: North America Recombinant Vaccines Market Value (USD billion), by Distribution Channel, 2025 & 2034
  • Figure 14: North America Recombinant Vaccines Market Value Share (%), by Distribution Channel, 2025
  • Figure 15: North America Recombinant Vaccines Market Value (USD billion), By Country, 2025 & 2034
  • Figure 16: North America Recombinant Vaccines Market Value Share (%), By Country, 2025
  • Figure 17: Europe Recombinant Vaccines Market Value (USD billion), by Type, 2025 & 2034
  • Figure 18: Europe Recombinant Vaccines Market Value Share (%), by Type, 2025
  • Figure 19: Europe Recombinant Vaccines Market Value (USD billion), by Disease Indication, 2025 & 2034
  • Figure 20: Europe Recombinant Vaccines Market Value Share (%), by Disease Indication, 2025
  • Figure 21: Europe Recombinant Vaccines Market Value (USD billion), by Route of Administration, 2025 & 2034
  • Figure 22: Europe Recombinant Vaccines Market Value Share (%), by Route of Administration, 2025
  • Figure 23: Europe Recombinant Vaccines Market Value (USD billion), by Distribution Channel, 2025 & 2034
  • Figure 24: Europe Recombinant Vaccines Market Value Share (%), by Distribution Channel, 2025
  • Figure 25: Europe Recombinant Vaccines Market Value (USD billion), By Country/ Sub-region, 2025 & 2034
  • Figure 26: Europe Recombinant Vaccines Market Value Share (%), By Country/ Sub-region, 2025
  • Figure 27: Asia Pacific Recombinant Vaccines Market Value (USD billion), by Type, 2025 & 2034
  • Figure 28: Asia Pacific Recombinant Vaccines Market Value Share (%), by Type, 2025
  • Figure 29: Asia Pacific Recombinant Vaccines Market Value (USD billion), by Disease Indication, 2025 & 2034
  • Figure 30: Asia Pacific Recombinant Vaccines Market Value Share (%), by Disease Indication, 2025
  • Figure 31: Asia Pacific Recombinant Vaccines Market Value (USD billion), by Route of Administration, 2025 & 2034
  • Figure 32: Asia Pacific Recombinant Vaccines Market Value Share (%), by Route of Administration, 2025
  • Figure 33: Asia Pacific Recombinant Vaccines Market Value (USD billion), by Distribution Channel, 2025 & 2034
  • Figure 34: Asia Pacific Recombinant Vaccines Market Value Share (%), by Distribution Channel, 2025
  • Figure 35: Asia Pacific Recombinant Vaccines Market Value (USD billion), By Country/ Sub-region, 2025 & 2034
  • Figure 36: Asia Pacific Recombinant Vaccines Market Value Share (%), By Country/ Sub-region, 2025
  • Figure 37: Latin America Recombinant Vaccines Market Value (USD billion), by Type, 2025 & 2034
  • Figure 38: Latin America Recombinant Vaccines Market Value Share (%), by Type, 2025
  • Figure 39: Latin America Recombinant Vaccines Market Value (USD billion), by Disease Indication, 2025 & 2034
  • Figure 40: Latin America Recombinant Vaccines Market Value Share (%), by Disease Indication, 2025
  • Figure 41: Latin America Recombinant Vaccines Market Value (USD billion), by Route of Administration, 2025 & 2034
  • Figure 42: Latin America Recombinant Vaccines Market Value Share (%), by Route of Administration, 2025
  • Figure 43: Latin America Recombinant Vaccines Market Value (USD billion), by Distribution Channel, 2025 & 2034
  • Figure 44: Latin America Recombinant Vaccines Market Value Share (%), by Distribution Channel, 2025
  • Figure 45: Latin America Recombinant Vaccines Market Value (USD billion), By Country/ Sub-region, 2025 & 2034
  • Figure 46: Latin America Recombinant Vaccines Market Value Share (%), By Country/ Sub-region, 2025
  • Figure 47: Middle East & Africa Recombinant Vaccines Market Value (USD billion), by Type, 2025 & 2034
  • Figure 48: Middle East & Africa Recombinant Vaccines Market Value Share (%), by Type, 2025
  • Figure 49: Middle East & Africa Recombinant Vaccines Market Value (USD billion), by Disease Indication, 2025 & 2034
  • Figure 50: Middle East & Africa Recombinant Vaccines Market Value Share (%), by Disease Indication, 2025
  • Figure 51: Middle East & Africa Recombinant Vaccines Market Value (USD billion), by Route of Administration, 2025 & 2034
  • Figure 52: Middle East & Africa Recombinant Vaccines Market Value Share (%), by Route of Administration, 2025
  • Figure 53: Middle East & Africa Recombinant Vaccines Market Value (USD billion), by Distribution Channel, 2025 & 2034
  • Figure 54: Middle East & Africa Recombinant Vaccines Market Value Share (%), by Distribution Channel, 2025
  • Figure 55: Middle East & Africa Recombinant Vaccines Market Value (USD billion), By Country/ Sub-region, 2025 & 2034
  • Figure 56: Middle East & Africa Recombinant Vaccines Market Value Share (%), By Country/ Sub-region, 2025
  • Figure 57: Global Recombinant Vaccines Market Share (%), By Company, 2025